A Glimpse Into The Expert Outlook On Fusion Pharmaceuticals Through 7 Analysts
Portfolio Pulse from Benzinga Insights
Fusion Pharmaceuticals (NASDAQ:FUSN) has been evaluated by 7 analysts over the past three months, showing a mix of bullish and somewhat bullish perspectives. The average 12-month price target for FUSN has increased to $14.29, up 9.92% from the previous target of $13.00. Analysts from firms including RBC Capital, Wedbush, Oppenheimer, and Raymond James have adjusted their ratings and price targets, reflecting a positive outlook on the company's performance. Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company, has shown significant revenue growth and strong financial health, despite carrying a substantial amount of debt.
March 04, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Fusion Pharmaceuticals has received positive evaluations from analysts, with an updated average 12-month price target of $14.29. The company's significant revenue growth and strong financial health are highlighted, despite its high debt levels.
The positive shift in analyst ratings and the increase in the average price target to $14.29 reflect a bullish outlook on FUSN. The company's substantial revenue growth and financial metrics, despite its debt, contribute to this positive assessment. The recent analyst actions, including raised price targets and maintained outperform ratings, indicate a strong belief in the company's future performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100